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The DNA single-strand break repair (SSBR) protein XRCC1 is required for genetic stability and for
embryonic viability. XRCC1 possesses two BRCA1 carboxyl-terminal (BRCT) protein interaction domains,
denoted BRCT I and II. BRCT II is required for SSBR during G1 but is dispensable for this process during
S/G2 and consequently for cell survival following DNA alkylation. Little is known about BRCT I, but this
domain has attracted considerable interest because it is the site of a genetic polymorphism that epidemiolog-
ical studies have associated with altered cancer risk. We report that the BRCT I domain comprises the
evolutionarily conserved core of XRCC1 and that this domain is required for efficient SSBR during both G1 and
S/G2 cell cycle phases and for cell survival following treatment with methyl methanesulfonate. However, the
naturally occurring human polymorphism in BRCT I supported XRCC1-dependent SSBR and cell survival
after DNA alkylation equally well. We conclude that while the BRCT I domain is critical for XRCC1 to
maintain genetic integrity and cell survival, the polymorphism does not impact significantly on this function
and therefore is unlikely to impact significantly on susceptibility to cancer.
Thousands of DNA single-strand breaks (SSBs) arise in cells
each day both directly by the disintegration of damaged sugars
and indirectly as intermediates of base excision repair (BER)
(4, 29). If not repaired, SSBs pose a threat to both genetic
stability and cell survival, resulting in an increased frequency of
mutations and chromosome aberrations (15, 23, 38, 50, 53, 56).
The threat posed by unrepaired SSBs most likely reflects their
ability to become double-strand breaks during chromosome
replication (27). The enzymatic pathways adopted by cells for
DNA SSB repair (SSBR) can be divided into four basic steps,
involving damage detection, end processing, gap filling, and
DNA ligation (see reference 8 for a review). For example, in
the case of direct SSBs arising from sugar damage or sponta-
neous cleavage at abasic sites, the breaks are most likely de-
tected by poly(ADP-ribose) polymerase 1 (PARP-1) or poly-
(ADP-ribose) polymerase 2 (PARP-2) (3, 18–20, 52). Next,
damaged 3 or 5 termini present at the breaks are converted
to conventional 3-hydroxyl and 5-phosphate chemistries by
AP endonuclease (APE1/HAP1), DNA polymerase  (Pol),
or polynucleotide kinase (PNK). Finally, SSBR is completed by
gap filling by Pol or Pol/ε and DNA ligation by DNA ligase
I (Lig1) or DNA ligase III (Lig3).
A feature of mammalian SSBR appears to be the employ-
ment of protein-protein interactions to stimulate individual
component steps and/or the overall repair reaction. Arguably
the most intriguing SSBR protein in this respect is XRCC1
(X-ray repair cross-complementing group 1), a polypeptide
that interacts with PARP-1 (9, 33), PNK (54), Pol (9, 26), and
Lig3 (10, 11) (reviewed in references 8 and 51). The interac-
tion of XRCC1 with PNK stimulates both the 5-kinase and
3-phosphatase activities of this enzyme (54), and the interac-
tion with Lig3 increases the intracellular stability of the ligase
(11, 46). Studies have demonstrated a role for XRCC1 both in
vitro and in vivo during the repair of either direct SSBs or
those arising indirectly during BER (13, 14, 16, 17, 21, 48, 49,
54). Consistent with this, rodent cells lacking XRCC1 are hy-
persensitive to a broad range of genotoxins (7, 13, 15–17, 49,
56). Loss of XRCC1 also results in decreased genetic stability,
including increased frequencies of spontaneous and/or induced
chromosome translocations and deletions (15, 23, 49, 53, 56).
Given the number of protein-protein interactions involving
XRCC1 it is important to identify the contribution made by
each to genetic stability. To achieve this we are systematically
mutating the individual protein binding domains within
XRCC1. A striking feature of XRCC1 is the presence of two
BRCA1 carboxyl-terminal (BRCT) domains, denoted BRCT I
and BRCT II, that are located centrally and at the C terminus
of this polypeptide, respectively (5, 12). The C-terminal do-
main is responsible for binding and stabilizing Lig3 (31, 37,
47) and is required for SSBR specifically during the G0/G1
phase of the cell cycle (36, 46). In contrast, little is known
about the role of the central BRCT I domain. However, this
domain has become the focus of considerable interest since it
was identified as the site of a common human genetic poly-
morphism (R399Q) that appears from a large number of epi-
demiological studies to impact significantly on cancer risk (1, 2,
6, 22, 24, 28, 34, 41–45). This polymorphism has been reported
to both increase and decrease cancer frequencies, depending
on the type and location of the cancer. In addition, a correla-
tion has been reported between the presence of the 399Q allele
and levels of DNA damage, mutation, and ionizing radiation-
induced mitotic delay (25, 30, 35). Although provocative, these
epidemiological studies are difficult to interpret because little
is known about the role and importance of the BRCT I domain
and because of the variation in genetic background that is
intrinsic to such studies. Here, we have directly examined the
importance of the BRCT I domain to cell survival and SSBR in
* Corresponding author. Present address: Genome Damage and
Stability Centre, University of Sussex, Falmer, Brighton BN1 9RR,
United Kingdom. Phone: 01273 678123. Fax: 01273 678121. E-mail:
k.w.caldecott@sussex.ac.uk.
2556
 o
n
 June 19, 2014 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
an isogenic cellular background and examined the impact of
the common R399Q polymorphism on these processes.
MATERIALS AND METHODS
Expression constructs and Arabidopsis thaliana XRCC1. The mammalian cell
expression vector pcD2E and the derivative pcD2EXH, which encodes C-termi-
nally histidine-tagged XRCC1 (XRCC1-His), have been described previously
(10). Derivatives of pcD2EXH harboring mutations within the BRCT I domain
were created by site-directed mutagenesis using the QuikChange protocol (Strat-
agene). The sequence of all resulting open reading frames was confirmed by
sequencing. The sequence of the A. thaliana XRCC1 was obtained by direct
sequencing of the lambda PRL2 clone, 210J9T7, obtained from the Arabidopsis
Biological Research Center (Ohio State University).
Cell culture. CHO cells were cultured as monolayers or in suspension as
appropriate in alpha-minimal essential medium supplemented with 10% fetal
bovine serum (GibcoBRL). Expression constructs were introduced into EM9
cells by calcium phosphate coprecipitation, and stable clones were selected in the
presence of G418 (1.5 mg/ml) for 10 to 14 days.
Cell extracts and affinity purification of histidine-tagged XRCC1 protein com-
plexes. Whole-cell extracts were prepared from frozen pellets of transfected
EM9 cells (1  107 to 3  107) by resuspension in 1.5 ml of lysis buffer (50 mM
Tris-Cl [pH 7.5], 130 mM NaCl, 0.5% Triton X-100, 10% glycerol, 1 mM dithio-
threitol, 1/20 dilution of protease inhibitor cocktail [Sigma P8340]) and incuba-
tion on ice for 30 min. High-molecular-weight DNA was sheared by passage
through a narrow-gauge needle several times, and insoluble material was re-
moved by centrifugation in a microcentrifuge for 5 min at 4°C. To affinity-purify
histidine-tagged XRCC1 complexes, clarified protein extracts (1.5 ml) from the
different EM9 transfectants were incubated in parallel with 0.5 ml (bed volume)
of nickel-nitrilotriacetic acid (NTA)-agarose (Qiagen) prewashed in lysis buffer
and incubated with gentle agitation on ice for 30 min. The resulting suspensions
were added to disposable 5-ml chromatography columns (Polyprep; Bio-Rad),
and the protein-agarose beads were washed with 10 column volumes of lysis
buffer containing 20 mM imidazole. Histidine-tagged XRCC1 protein complexes
were eluted with 10 column volumes of lysis buffer containing 250 mM imidazole,
with 0.25- to 0.5-ml fractions collected dropwise.
Indirect immunofluorescence. Immunofluorescence was conducted as de-
scribed previously (46). Images were captured at 400 magnification.
SSBR assays. Single cell agarose gel electrophoresis was conducted on asyn-
chronous or synchronized populations of CHO cells as described previously (36,
46).
Survival curves. Survival curves describing the resistance of transfected CHO
cells to methyl methanesulfonate (MMS) were obtained as described previously,
for ethyl methanesulfonate (46).
Nucleotide sequence accession number. The sequence of the open reading
frame of A. thaliana XRCC1 was placed in GenBank (accession number
AJ276506).
RESULTS
To examine the biological importance of the BRCT I do-
main, mutations were created that were analogous to those
previously shown to disrupt the folding (57) and activity (36,
46, 47) of the BRCT II domain (Fig. 1A). These mutations lie
within the 3 sheet (LI360/361DD) and the highly conserved
3 helix (W385D) (Fig. 1B). The mutation in the 3 helix is
particularly noteworthy, since it removes the tryptophan resi-
due that is present in almost all BRCT domains (5, 12). Empty
pcD2E expression vector or pcD2E constructs encoding
wild-type (pcD2EXH) or mutant (pcD2EXHLI360/361DD or
pcD2EXHW385D) histidine-tagged XRCC1 were transfected
into XRCC1 mutant EM9 cells by calcium phosphate copre-
cipitation. For further analysis we attempted to isolate single
clones that possessed similar levels of wild-type or mutant
XRCC1, as measured by indirect immunofluorescence and
immunoblotting. In the clones selected, the level of mutant
XRCC1W385D was essentially the same as the level of wild-type
XRCC1, whereas the level of XRCC1LI360/361DD was approx-
imately half this amount (Fig. 2A and B). A hallmark pheno-
type of XRCC1 mutant cells is hypersensitivity to MMS (49).
Whereas pcD2EXH was able to restore wild-type levels
of resistance to MMS, neither pcD2EXHLI360/361DD nor
pcD2EXHW385D increased survival much above that observed
in EM9 cells expressing empty pcD2E vector (Fig. 2C). In
agreement with these data, EM9 cells harboring either
pcD2EXHLI360/361DD or pcD2EXHW385D were also unable to
survive culture conditions in which 20% of genomic thymine
base is replaced with chlorouracil during cell division, condi-
tions that are lethal to cells lacking XRCC1 but which do not
affect the survival of cells expressing wild-type XRCC1 (data
not shown). The inability of pcD2EXHLI360/361DD and
pcD2EXHW385D to complement the MMS sensitivity of EM9
cells did not reflect the use of single clones, since similar results
were observed with pooled populations of 100 clones (data
not shown). The lack of cellular complementation by
pcD2EXHLI360/361DD similarly did not simply reflect the lower
level of expression of XRCC1LI360/361DD, since wild-type
XRCC1 or XRCC1 harboring the analogous mutation in the
BRCT II domain fully restores resistance to the alkylating
agent even at protein levels that are undetectable by immuno-
blotting (36; unpublished observations).These data suggest
that mutation of the BRCT I domain disrupts the ability of
XRCC1 to promote cell survival following MMS treatment.
This contrasts dramatically with the BRCT II domain, which is
largely dispensable for MMS resistance in cycling CHO cells
(36, 46).
To examine whether the mutated BRCT I domain disrupts
SSBR, this process was measured in transfected EM9 cell using
alkaline agarose single-cell gel electrophoresis. This technique,
also known as the comet assay, measures DNA strand breaks
by their ability to increase the amount of DNA that exits the
cell nucleus, and the distance migrated by this DNA, under an
electric field. DNA damage is expressed graphically as the tail
moment, an arbitrary unit reflecting the product of these two
parameters. In EM9-V cells lacking XRCC1-dependent SSBR,
tail moment increased linearly with doses of up to 0.5 mg of
MMS/ml (Fig. 3A), and so a concentration of 0.3 mg/ml was
chosen for subsequent experiments. Whereas the level of SSBs
in EM9-XH cells rose 15-fold during MMS treatment, the
level in EM9-V, EM9-XHLI360/361DD, and EM9-XHW385D cells
rose30-fold (Fig. 3B). A difference between repair-proficient
and mutant EM9 cells in the level of SSBs accumulated during
DNA alkylation has been noted previously and is due to a
differential ability to repair SSBs during drug treatment (36,
46, 49). Thus, the observation that EM9-XHLI360/361DD and
EM9-XHW385D accumulated levels of SSBs similar to those of
EM9-V rather than EM9-XH suggests that the former cell
lines are SSBR defective. This was confirmed during a subse-
quent repair incubation in drug-free medium, because the
level of MMS-induced SSBs in EM9-XH cells dropped by
40% within 20 min whereas the level in EM9-V and EM9-
XHW385D cells appeared to increase by 20% (Fig. 3B). This
increase in the last two cell lines most likely reflects continued
excision of damaged bases in the absence of efficient SSB
rejoining. The number of MMS-induced SSBs removed by
EM9-XHLI360/361DD and EM9-XHW385Dcells was also no
greater than that removed by EM9-V cells after a repair incu-
bation of 180 min (Fig. 3B), further suggesting that the mu-
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tated BRCT I domain ablated XRCC1-dependent SSBR. It
was noted that some residual SSBR was present in EM9-V,
EM9-XHLI360/361DD, and EM9-XHW385Dcells, however, since
after the initial increase the level of MMS-induced SSBs
dropped by 40 to 60% by the end of the experiment (Fig. 3B).
Residual SSBR in XRCC1-deficient cell lines has been noted
previously (49) and is consistent with the activity of an
XRCC1-independent SSBR process such as that occurring
during BER mediated by PCNA, DNA polymerase /ε, and
Lig1 (reviewed in reference 8).
Mutation of the BRCT II domain selectively ablates
XRCC1-dependent SSBR in G0/G1 phases of the cell cycle (8,
36, 46). To examine whether mutation of the BRCT I domain
similarly ablates SSBR in a cell cycle-specific manner, SSBR
was measured in cells that were synchronized in G1 or S/G2
phase prior to MMS treatment (Fig. 4a). Synchronization was
achieved as previously described (36, 39, 46) by a combination
of serum starvation and mimosine to arrest the cells at the G1/S
boundary (39). We have shown previously by BrdUrd pulse-
labeling that populations of CHO cells synchronized in this
way do not possess replicating cells (36). The steady-state level
of SSBs increased 20-fold in each of the cell lines during
treatment with MMS in G1 (Fig. 4B, top panel). Once again,
neither EM9-XHLI360/361DD nor EM9-XHW385D cells removed
significantly more MMS-induced SSBs during a 3-h repair in-
cubation than did EM9-V cells, with 30% removed in these
cell lines compared to 90% in EM9-XH cells (Fig. 4B, top
panel). Similar results were observed in cells synchronized in
the S/G2 phase of the cell cycle, with the level of SSBs remain-
ing in EM9-XHLI360/361DD and EM9-XHW385D cells after 3 h
similar to those present in EM9-V cells (Fig. 4B, bottom pan-
el). These data indicate that in contrast to the BRCT II do-
main, mutation of the BRCT I domain ablates XRCC1-depen-
dent SSBR in both G1 and S/G2 phases of the cell cycle.
XRCC1 contains two other known protein-protein interac-
tion domains in addition to the BRCT I domain. These are the
N-terminal domain (NTD) and the BRCT II domain, which
together flank the central BRCT I domain (see Fig. 1A) and
which mediate interactions with Pol and Lig3, respectively
(26, 31, 32, 37, 47). It was considered possible that mutation of
the BRCT I domain may have ablated XRCC1-dependent
SSBR indirectly, by interfering with the function of one or both
FIG. 1. (A) XRCC1 protein-protein interaction domains. The location of the NTD and the two BRCT domains within XRCC1 are indicated.
The location of mutations in BRCT II previously employed (36, 46, 47) to disrupt activity of this domain, and the analogous BRCT I mutations
employed in this study, are shown. Also shown is the location of the common human genetic polymorphism in BRCT I, R399Q. (B) CD alignment
(NCBI) of the pfam00533 consensus BRCT domain with BRCT domains present in XRCC1, Lig3, and BRCA1. Boxed residues denote regions
of hydrophobicity (with hydrophobic residues in boldface) that are conserved in the BRCT family, with those in dark grey denoting those that are
most conserved. The position of secondary structure, based on the crystal structure of the BRCT II domain of XRCC1 (57), is shown at the top
and bottom. The amino acids mutated to aspartate (D) in this study, and the position of the common human polymorphism (Q) is also indicated.
2558 TAYLOR ET AL. MOL. CELL. BIOL.
 o
n
 June 19, 2014 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
of these domains. To examine this possibility, the presence of
Pol and Lig3 in XRCC1 protein complexes affinity purified
from EM9-XH and EM9-XHW385D cells was measured by im-
munoblotting. These experiments revealed that similar
amounts of Pol and Lig3 copurified with XRCC1 complexes
from EM9-XH and EM9-XHW385D cell extract (Fig. 5), sug-
gesting that the inability of XRCC1W385D to support SSBR was
not due to the W385D mutation interfering with the domains
that bind these proteins. Rather, these experiments suggest
that the inability of XRCC1W385D to support SSBR reflects a
direct requirement for the BRCT I domain for this process.
Several common polymorphisms have been described in
XRCC1 that are overrepresented or underrepresented in individ-
uals with certain types of cancer (1, 2, 6, 22, 24, 28, 34, 41–45).
Intriguingly, the polymorphism most commonly reported to affect
cancer risk is R399Q, which is located at the C terminus of the
BRCT I domain (see Fig. 1). The allele frequency of 399Q is 15
to 30%, based on studies conducted so far, resulting in a high
frequency of individuals (5 to 15%) that are homozygous for this
allele. In addition, a correlation has been reported between the
presence of the 399Q allele and levels of DNA damage, mutation,
and ionizing radiation-induced mitotic delay (25, 30, 35). We
FIG. 2. Characterization of EM9 cells expressing wild-type or mutant XRCC1. (A) XRCC1 protein was examined in the indicated cell lines by
indirect immunofluorescence, using the primary anti-XRCC1 MAb 33-2-5 and a fluorescein isothiocyanate-conjugated rabbit antimouse secondary
antibody (DAKO). Nuclei were visualized with the DNA stain 4,6-diamidino-2-phenylindole. Photographs were taken under 400 magnification.
(B) XRCC1 protein levels were examined in cell extracts (20 	g of total protein) from the indicated cell lines (XH, EM9-XH; 360/361,
EM9-XHLI360/361DD; 385, EM9-XHW385D; V, EM9-V) by immunoblotting, using the anti-XRCC1 MAb 33-2-5. (C) The cell lines indicated (see
panel A for an explanation of symbols) were plated in six-well dishes (200 cells/well) and treated with the indicated concentrations of MMS for
1 h. After a wash, cells were incubated in drug-free medium for 7 to 10 days to allow formation of macroscopic colonies. The fraction of cells
surviving MMS treatment was calculated by dividing the number of colonies in treated wells by the number in untreated wells. Results are the mean

 1 standard deviation of three independent experiments.
FIG. 3. Measurement of MMS-induced SSBs in asynchronous populations of transfected EM9 cells. (A) EM9-V cells were treated for 15 min
with the indicated concentrations of MMS, and the level of SSBs was quantified by alkaline agarose gel electrophoresis (comet assay). SSB levels
are expressed as the tail moment, an arbitrary unit reflecting the product of the amount of DNA present in the “comet” tail and the tail length,
after electrophoresis. (B) SSBs were quantified in the indicated EM9 transfectants before treatment for 15 min with 0.3 mg of MMS/ml (U,
untreated), immediately after MMS treatment (T, treated), or after a subsequent repair incubation in drug-free medium for 20 min (R20) or 3 h
(R180). Results are the average from four independent experiments (
1 standard deviation). The asterisk denotes the absence of a data point for
a 20-min repair incubation in EM9-XHLI360/361DD cells.
VOL. 22, 2002 THE XRCC1 BRCT I DOMAIN AND DNA STRAND BREAK REPAIR 2559
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therefore examined directly whether the two isoforms of
XRCC1 differed in their ability to support XRCC1-dependent
cell survival and SSBR following exposure to MMS. Analysis of
pooled populations of EM9 transfectants harboring pcD2E,
pcD2EXH, or pcD2EXHR399Q failed to reveal any difference
in the sensitivity of these cell lines to MMS (Fig. 6A). The
lack of quantitative difference between the MMS sensitivi-
ties of EM9XH and EM9XHR399Q cell populations (in both
of which 90% of individual clones expressed recombinant
XRCC1) did not reflect differences in steady-state levels of
XRCC1, since similar levels of this protein were observed in
these cell lines (Fig. 6B). We also examined the 399Q allele
for the ability to support SSBR following treatment with
MMS. XRCC1R399Q removed an amount of single-strand
breakage similar to that removed by wild-type XRCC1 dur-
ing a 3-h repair-incubation, suggesting that the two isoforms
are not significantly different in SSBR capacity (Fig. 6C
and D).
DISCUSSION
The BRCT I domain is required for XRCC1 function during
SSBR and for resistance to MMS. XRCC1 is important for
genetic stability and for embryonic viability (23, 48, 49). This
polypeptide appears to function as a scaffold protein that me-
diates the assembly of SSBR protein complexes (8, 54). To
examine the contribution of individual protein interactions to
SSBR, we have been systematically mutating individual protein
FIG. 4. Measurement of MMS-induced SSBs in synchronized populations of EM9 transfectants. (A) DNA content of EM9-V cells synchro-
nized in G1 (top panel) or S/G2 (bottom panel) by serum starvation and mimosine as described previously (36, 39, 46). Similar synchrony was
observed with other EM9 transfectants (data not shown). The respective arrows denote peak positions of cells with G1 and G2 DNA content.
(B) SSBs were quantified in the indicated EM9 transfectants in G1 (top panel) or S/G2 (bottom panel) before treatment for 15 min with 0.3 mg
of MMS/ml (U, untreated), immediately after MMS treatment (T, treated), or after a subsequent repair incubation in drug-free medium for 3 h
(R180). Results are the mean (
1 standard deviation) from three independent experiments.
FIG. 5. Presence of Lig3 and Pol in affinity-purified XRCC1 pro-
tein complexes. Total cellular protein (20 	g) from the cell lines
indicated on the left was subjected to metal chelate affinity chroma-
tography (nickel agarose; Qiagen) to purify histidine-tagged XRCC1
protein complexes. Aliquots of the recovered complexes were sub-
jected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis
and immunoblotted with anti-XRCC1 MAb (33-2-5), anti-Lig3 Pab
(TL-25), or anti-Pol MAb (Clone 18S; Lab Vision).
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binding domains within XRCC1. Two such domains are BRCT
I and BRCT II, which are located in the center and C terminus
of the polypeptide, respectively (5, 12). We reported previously
that the BRCT II domain mediates interaction with Lig3 and
is required for XRCC1-dependent SSBR during G0/G1 phases
of the cell cycle (36, 46). However, this domain is largely
dispensable for XRCC1-dependent SSBR during S/G2 phase
and consequently for cellular resistance to alkylating agents
(46). In contrast to BRCT II, we report here that mutation of
the BRCT I domain ablates XRCC1-dependent SSBR in both
G1 and S/G2 and also prevents XRCC1 from maintaining cell
survival after DNA alkylation.
It seems unlikely that the BRCT I mutations ablate XRCC1-
dependent SSBR through an indirect effect on regions located
outside of this domain. This is because these mutations did not
disrupt binding of XRCC1 to either Pol or Lig3, two inter-
actions known to occur within XRCC1 domains that flank the
BRCT I domain. Rather, these data suggest a direct require-
ment for the BRCT I domain for SSBR in G1 and S/G2 and for
cellular resistance to MMS.
The suggestion that the BRCT I domain is a fundamental
component of XRCC1 function is supported by the compari-
son of XRCC1 homologues in different species. Whereas the
BRCT II domain is present in human and other mammalian
species, it is absent from both Drosophila melanogaster and A.
thaliana XRCC1 (Fig. 7). In contrast, the BRCT I domain is
present in all XRCC1 homologues so far identified.
Biochemical role of the BRCT I domain. In contrast to the
BRCT II domain, the BRCT I domain appears to be indis-
pensable for XRCC1-dependent SSBR in both G1 and S/G2.
What biochemical role does the BRCT I domain fulfill? This
domain does not appear to be required for XRCC1 to assem-
ble into discrete subnuclei foci (see Fig. 2A), structures previ-
ously shown to assemble primarily during S phase and in re-
sponse to DNA damage (46). However, in addition to Pol and
Lig3, XRCC1 also interacts with PARP-1 (9, 33), and the site
of this interaction is located within the BRCT I domain (33). It
is likely that the interaction with PARP-1 may serve to recruit
XRCC1 protein complexes to sites of single-strand breakage,
since XRCC1 preferentially binds the activated form of
PARP-1 that arises once the latter polypeptide has bound an
SSB (33, 40). This ability to discriminate between active and
inactive PARP-1 most likely reflects the ability of XRCC1 to
bind poly(ADP-ribose), the polymeric product of PARP-1 ac-
tivity (40). Further work is required to determine whether or
not binding by the XRCC1 BRCT I domain to PARP-1 and
poly(ADP-ribose) can account for the importance of this do-
main to SSBR and cell survival.
It is also possible that the BRCT I domain mediates the
recently identified interaction of XRCC1 with PNK (54). This
interaction stimulates the activity of PNK at SSB termini,
thereby enabling restoration of the conventional 3-hydroxyl
and 5-phosphate chemistry required for completion of SSBR
by gap filling and DNA ligation. Finally, it is possible that
BRCT I also interacts with an as yet unidentified polypeptide
or that it fulfills some other role. For example, it has been
reported that BRCT domains can bind DNA directly, though
the physiological significance of this is unclear (55). Clearly,
given the importance of the BRCT I domain to XRCC1 func-
tion and genetic integrity, it is important to identify the role/s
fulfilled by this structure.
FIG. 6. MMS sensitivity and SSBR capacity of EM9 cells harboring
the human genetic polymorphism XRCC1R399Q. (A) The indicated cell
lines (pooled populations of 100 independent transfectants) were
plated in six-well dishes (200 cells/plate) and treated with the indicated
concentration of MMS for 1 h. After a wash, cells were incubated in
drug-free medium for 7 to 10 days to allow formation of macroscopic
colonies, and the fraction of surviving cells was calculated as described
in the legend for Fig. 2. (B) Total cellular protein (20 	g) from the
indicated cell lines was fractionated by SDS-PAGE and immunoblot-
ted with the anti-XRCC1 MAb, 33-2-5. (C) SSBs (expressed as tail
moments) were quantified in the indicated EM9 transfectants before
(MMS) or immediately after (MMS) treatment with 0.3 mg of
MMS/ml. (D) The percentage of the MMS-induced SSBs shown in
panel C remaining after a 3-h repair incubation in drug-free medium
(calculated from the tail moment present after the repair incubation).
Symbols are as in panel C. Results are the mean 
 1 standard devia-
tion for three independent experiments.
FIG. 7. Evolutionary conservation of XRCC1 protein domains.
Human (Hu), D. melanogaster (Dm), and A. thaliana (At) XRCC1
homologues were aligned using MACAW software, with vertical bars
denoting conserved residues and enlarged boxes denoting regions of
extensive conservation. The dotted box denotes the position of the
BRCT II domain present in mammalian XRCC1 (represented here by
the human protein). The domains identified by this alignment are the
NTD, which contains the binding site for Pol, and the two BRCT
domains, which contain the binding sites for PARP-1, poly(ADP-ri-
bose), and Lig3. The Hu and Dm BRCT I domains, and the Hu and
At BRCT I domains, share 54.5 and 52.8% identity, respectively.
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A human polymorphism within BRCT I. One class of genetic
factors that are likely to contribute to cancer predisposition is
genetic polymorphisms. The XRCC1 BRCT I domain has re-
cently attracted considerable interest because of the identifi-
cation of a common genetic polymorphism (R399Q) at the C
terminus of the BRCT I domain (43). Intriguingly, a large
number of studies have reported an overrepresentation of one
allele over the other among groups of individuals with a variety
of cancers, including those of the lung, breast, bladder, and
esophagus (1, 2, 6, 22, 24, 28, 34, 41–45). The explanation
suggested for overrepresentation of one or another of the
XRCC1 alleles among cancer groupings has been that the
polymorphism impacts upon the activity of XRCC1 and con-
sequently on SSBR efficiency and genetic stability. Consistent
with this, a correlation has also been reported between the
presence of the 399Q allele and levels of DNA damage, mu-
tation, and ionizing radiation-induced mitotic delay (25, 30,
35).
Although provocative, such epidemiological studies are dif-
ficult to interpret in lieu of functional data concerning the
impact of the polymorphism on protein function. Moreover,
there is currently no clear consensus among the epidemiolog-
ical studies as to which of the alleles is detrimental. A further
complication with respect to XRCC1 is the additional location
of several other DNA repair genes within the region of chro-
mosome 19q13.2-13.3, such as ERCC1, ERCC2, DNA ligase I,
and polynucleotide kinase, that could harbor polymorphisms
that contribute to the apparent impact of the XRCC1 poly-
morphism. To circumvent these problems, in this study we
compared directly for the first time the two XRCC1 isoforms
for their ability to conduct SSBR and mediate cell survival in
an isogenic background. In these experiments the two alleles
were equally able to complement both the SSBR defect and
sensitivity to MMS observed in XRCC1-deficient EM9 cells.
Given that the BRCT I domain is critical to these functions,
these experiments suggest that the polymorphism has little
effect on the BRCT I domain or XRCC1 function.
In summary, we report that the BRCT I domain comprises
the evolutionarily conserved core motif of XRCC1 and that
this domain is critical for efficient SSBR and cell survival.
However, the common human polymorphism located within
this domain does not appear to significantly affect the ability of
the BRCT I domain to support either of these processes fol-
lowing DNA alkylation, suggesting that it is unlikely to impact
significantly on susceptibility to cancer.
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